Currently, the decision to introduce anti-TNFα treatment is evaluated based on high disease activity, in clinical practice usually assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and a lack of improvement in previous treatment. This evidence concerns the gene TNF and ankylosing spondylitis.